CD274 and non-small cell lung carcinoma: Furthermore, PD-L1 status had a clear and significant impact on stratifying OS in the KRASMUT group receiving treatment, whereas no difference was observed for the KRASWT group, which is in line with a previous study reporting a similar trend for KRASMUT NSCLC patients receiving ICB treatment [35].